Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
- 25 May 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 377 (9782), 2013-2022
- https://doi.org/10.1016/s0140-6736(11)60600-4
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trialThe Lancet Neurology, 2010
- Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular eventsThe Lancet Neurology, 2010
- New P2Y 12 InhibitorsCirculation, 2010
- Antithrombotic Agents in the Prevention of Ischemic StrokeCerebrovascular Diseases, 2009
- Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent StrokeNew England Journal of Medicine, 2008
- Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic AttackStroke, 2006
- Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trialThe Lancet, 2004
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of strokeJournal of the Neurological Sciences, 1996